These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 6097705)

  • 1. [Pharmacological mechanism of modern diuretics. Aldosterone antagonists].
    Kinouchi T; Shimizu N
    Nihon Rinsho; 1984 Sep; 42(9):1994-2000. PubMed ID: 6097705
    [No Abstract]   [Full Text] [Related]  

  • 2. Spironolactone for heart failure.
    Med Lett Drugs Ther; 1999 Sep; 41(1061):81-2. PubMed ID: 10505071
    [No Abstract]   [Full Text] [Related]  

  • 3. Spironolactone and ACE inhibition in chronic renal failure.
    Epstein FH
    N Engl J Med; 2002 Feb; 346(6):456-7. PubMed ID: 11832542
    [No Abstract]   [Full Text] [Related]  

  • 4. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.
    Chrysostomou A; Pedagogos E; MacGregor L; Becker GJ
    Clin J Am Soc Nephrol; 2006 Mar; 1(2):256-62. PubMed ID: 17699214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone antagonists in congestive heart failure.
    Soberman J; Chafin CC; Weber KT
    Curr Opin Investig Drugs; 2002 Jul; 3(7):1024-8. PubMed ID: 12186262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of action of aldosterone blockers.
    Fanestil DD
    Semin Nephrol; 1988 Sep; 8(3):249-63. PubMed ID: 2849183
    [No Abstract]   [Full Text] [Related]  

  • 7. Induction of cardiac fibrosis by aldosterone.
    Lijnen P; Petrov V
    J Mol Cell Cardiol; 2000 Jun; 32(6):865-79. PubMed ID: 10888242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
    Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
    Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
    Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well.
    Gullulu M; Akdag I; Kahvecioglu S; Filiz G; Savci V
    Ren Fail; 2006; 28(6):509-14. PubMed ID: 16928621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Aldosterone block in proteinuria].
    Kooter AJ; Smulders YM
    Ned Tijdschr Geneeskd; 2009 Apr; 153(15):710-4. PubMed ID: 19452774
    [No Abstract]   [Full Text] [Related]  

  • 13. Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism.
    Poggio R; Grancelli HO; Miriuka SG
    Postgrad Med J; 2010 Mar; 86(1013):136-42. PubMed ID: 20237007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacology of potassium-sparing diuretics].
    Dominiak P
    Praxis (Bern 1994); 1997 Apr; 86(14):552-5. PubMed ID: 9198848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upper gastrointestinal bleeding and spironolactone.
    Prescrire Int; 2011 Apr; 20(115):98-9. PubMed ID: 21648213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity.
    Pérez-Rojas JM; Derive S; Blanco JA; Cruz C; Martínez de la Maza L; Gamba G; Bobadilla NA
    Am J Physiol Renal Physiol; 2005 Nov; 289(5):F1020-30. PubMed ID: 15998842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Potassium-sparing diuretics].
    Shigetomi S; Fukuchi S
    Nihon Rinsho; 1992 Apr; 50 Suppl():680-5. PubMed ID: 1635256
    [No Abstract]   [Full Text] [Related]  

  • 18. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months.
    González Monte E; Andrés A; Polanco N; Toribio MJ; Santana R; Gutiérrez Martínez E; González J; Ramírez E; Hernández A; Morales E; Praga M; Morales JM
    Transplant Proc; 2010 Oct; 42(8):2899-901. PubMed ID: 20970564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options].
    Diercks GF; Overdiek JW; van Veldhuisen DJ
    Ned Tijdschr Geneeskd; 2001 Feb; 145(5):204-8. PubMed ID: 11219145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone induces collagen synthesis via activation of extracellular signal-regulated kinase 1 and 2 in renal proximal tubules.
    Xu G; Liu A; Liu X
    Nephrology (Carlton); 2008 Dec; 13(8):694-701. PubMed ID: 19154323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.